NEW YORK, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating a potential breach of fiduciary duty claim involving the board of directors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN).
On June 24, 2020, U.S. Department of Justice filed a lawsuit alleging that the Company has violated the False Claim Act and actively engaged in a kickback scheme to bolster its sale of macular degeneration drug, Eylea.
Beginning in 2012, the Company began to pay Chronic Disease Fund to cover Medicare co-pays for Eylea patients so the doctors would prescribe them, and the Company would make an estimated 400% profit. The Company has also been accused of lying to the government about their contributions to Chronic Disease Fund during a 2013 audit.
If you are a shareholder of Regeneron and wish to participate, learn more, or discuss the issues surrounding the investigation, please contact our attorneys at (914) 733-7256 or via email at investigations@lowey.com.
About Lowey Dannenberg
Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.
Contact
Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7256
Email: investigations@lowey.com